Back to Search
JOHN LEONARD, PH.D.
PH.D.
Clinical Psychologist
NPI: 1336226083Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
PSY12821(CA)
Research & Publications (20)
Reaching to multiple targets when standing: the spatial organization of feedforward postural adjustments.
PMID 19211658·J Neurophysiol·2009
8-other
Newborn screening for medium chain acyl CoA dehydrogenase deficiency.
PMID 18838415·Arch Dis Child·2009
6-review
Stability of zinc oxide nanofluids prepared with aggregated nanocrystalline powders.
PMID 19205207·J Nanosci Nanotechnol·2008
8-other
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
PMID 18853418·Cancer·2008
3-trial
Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
PMID 17452064·Eur J Med Chem·2008
8-other
Hypothesis: proposals for the management of a neonate at risk of hyperammonaemia due to a urea cycle disorder.
PMID 17436013·Eur J Pediatr·2008
8-other
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
PMID 18349031·Ann Oncol·2008
8-other
HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.
PMID 18996348·Cell Host Microbe·2008
8-other
The TLR3 signaling complex forms by cooperative receptor dimerization.
PMID 18172197·Proc Natl Acad Sci U S A·2008
8-other
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
PMID 18567989·Clin Adv Hematol Oncol·2008
6-review
Targeted treatment and new agents in diffuse large B-cell lymphoma.
PMID 18760704·Semin Hematol·2008
6-review
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
PMID 17470451·Ann Oncol·2007
3-trial
Systematic review of the risk of enteric infection in patients taking acid suppression.
PMID 17509031·Am J Gastroenterol·2007
1-meta
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
PMID 17530024·Oncogene·2007
6-review
Megafaunal extinctions and the disappearance of a specialized wolf ecomorph.
PMID 17583509·Curr Biol·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2659 PORTAGE BAY E, SUITE 204
DAVIS, CA 95616 - Phone
- (530) 756-6438
Quick Facts
- NPI
- 1336226083
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile